Read our Recent Headlines

June 21 Biotech Update

Sector strength continued and is clearly outperforming the broader market. While we have seen this happen for a couple days before, this feels more like a real breakout. Ideally, we.

Dave-Trading – June 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

June 20 Biotech Update

You would think replacing a computer would be an easy job, it apparently requires different layers of people and so not everyone was on campus yesterday. So at some point.

June 19 Biotech Update

The trade war is taking a lot of the headlines and I am running out of time to write as they are replacing my computer soon, which will likely take.

June 18 Biotech Update

Nothing new to start the week outside of a pretty weak market. I am not sure what the catalyst outside of an extended market but it looks again like the.

June 15 Biotech Update

EHA is here and there will be some updates that are of interest but for the most part, I do not see it as having a fundamental effect on the.

June 13 Biotech Update

The sector had a decent day, although participation was not great. We seem to be on the verge of breaking higher (at least in the XBI) but it will be.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!